Reduction of ischemic injury by nitroglycerin during acute myocardial infarction.
D000208:Acute Disease; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D003097:Collateral Circulation / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D003402:Creatine Kinase / Q000032:analysis; D004195:Disease Models, Animal; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000150:complications; D007511:Ischemia / Q000150:complications; D008729:Methoxamine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology; D005996:Nitroglycerin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D010656:Phenylephrine / Q000627:therapeutic use; D012018:Reflex; D013610:Tachycardia / Q000150:complications; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D010656:Phenylephrine; D003402:Creatine Kinase; D005996:Nitroglycerin; D008729:Methoxamine